Kupfer Lab - Revision history

Stacy A. Williams at 04:03, 30 November 2007

2007-11-30T04:03:11Z

←Older revision		Revision as of 04:03, 30 November 2007
Line 13:		Line 13:
	</div><br>		</div><br>

-	=='''Welcome to the Kupfer lab at ~~The~~ University ~~of Virginia~~'''==	+	=='''Welcome to the Kupfer lab at Yale University'''==
	[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]		[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]

Garykupfer: /* '''Welcome to the Kupfer lab at The University of Virginia''' */

2006-08-24T15:17:20Z

'''Welcome to the Kupfer lab at The University of Virginia'''

←Older revision		Revision as of 15:17, 24 August 2006
Line 24:		Line 24:
	Second, we are investigating ways to use our knowledge of genomic instability for improving cancer therapeutics. We have been working on tax1, a viral oncogene, in collaboration with the [http://www.evms.edu/micro/faculty-semmes.html/ Semmes laboratory at Eastern Virginia Medical School]. Interestingly, tax1 chemosensitizes p53 mutant cells in culture.		Second, we are investigating ways to use our knowledge of genomic instability for improving cancer therapeutics. We have been working on tax1, a viral oncogene, in collaboration with the [http://www.evms.edu/micro/faculty-semmes.html/ Semmes laboratory at Eastern Virginia Medical School]. Interestingly, tax1 chemosensitizes p53 mutant cells in culture.

-	Finally, we have also begun a more clinical project, using mass spectroscopy technology to find ~~FA binding proteins~~. Again in collaboration with the Semmes laboratory, we have adapted the mass spec to analyze sera from patients with ~~pediatric malignancies~~ in order to identify unique protein markers of disease.	+	Finally, we have also begun a more clinical project, using mass spectroscopy technology to find biomarkers in pediatric cancers. Again in collaboration with the Semmes laboratory, we have adapted the mass spec to analyze sera from patients with Hodgkin disease in order to identify unique protein markers of disease.

	== ==		== ==

Jwood1313 at 00:04, 18 August 2006

2006-08-18T00:04:37Z

←Older revision		Revision as of 00:04, 18 August 2006
Line 16:		Line 16:
	[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]		[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]

-	<font face="trebuchet ms" size="+1"> Our lab studies the relationship of genomic instability and the propensity towards development of cancer. Specifically, we focus on the genetic syndrome [http://www.fanconi.org/ Fanconi anemia] (FA). FA serves as a paradigm where the disciplines of development, genetics, and molecular oncology come together. Like other cancer susceptibility syndromes, such as [http://www.atcp.org/ ataxia telangiectasia] and [http://www.xps.org/ xeroderma pigmentosum,]FA patients exhibit a unique hypersensitivity to DNA crosslinking agents, which is the key to the biology of FA. Unlike the other syndromes, exceedingly little is known about FA. To learn more about FA, please visit our [http://openwetware.org/wiki/Kupfer_Lab:Research research link.]	+	<font face="trebuchet ms" size="+1">
		+
		+	Our lab studies the relationship of genomic instability and the propensity towards development of cancer. Specifically, we focus on the genetic syndrome [http://www.fanconi.org/ Fanconi anemia] (FA). FA serves as a paradigm where the disciplines of development, genetics, and molecular oncology come together. Like other cancer susceptibility syndromes, such as [http://www.atcp.org/ ataxia telangiectasia] and [http://www.xps.org/ xeroderma pigmentosum,]FA patients exhibit a unique hypersensitivity to DNA crosslinking agents, which is the key to the biology of FA. Unlike the other syndromes, exceedingly little is known about FA. To learn more about FA, please visit our [http://openwetware.org/wiki/Kupfer_Lab:Research research link.]

	We have three other ongoing projects related to FA. First, we have begun to purify the protein complexes containing gene products that are defective in 2 additional hematopoietic failure syndromes, [http://en.wikipedia.org/wiki/Diamond-Blackfan_anemia/ Diamond-Blackfan anemia (DBA)] and congenital dyserythropoietic anemia (CDA).		We have three other ongoing projects related to FA. First, we have begun to purify the protein complexes containing gene products that are defective in 2 additional hematopoietic failure syndromes, [http://en.wikipedia.org/wiki/Diamond-Blackfan_anemia/ Diamond-Blackfan anemia (DBA)] and congenital dyserythropoietic anemia (CDA).

Jwood1313 at 23:47, 17 August 2006

2006-08-17T23:47:49Z

←Older revision		Revision as of 23:47, 17 August 2006
Line 1:		Line 1:
-	[[Image:~~rotunda~~.jpg\|140px\|right]]	+	[[Image:UVArotunda.jpg\|140px\|right]]

Jwood1313 at 13:39, 15 August 2006

2006-08-15T13:39:53Z

←Older revision		Revision as of 13:39, 15 August 2006
Line 24:		Line 24:
	Finally, we have also begun a more clinical project, using mass spectroscopy technology to find FA binding proteins. Again in collaboration with the Semmes laboratory, we have adapted the mass spec to analyze sera from patients with pediatric malignancies in order to identify unique protein markers of disease.		Finally, we have also begun a more clinical project, using mass spectroscopy technology to find FA binding proteins. Again in collaboration with the Semmes laboratory, we have adapted the mass spec to analyze sera from patients with pediatric malignancies in order to identify unique protein markers of disease.

-	==~~Who is Visiting Us?~~==	+	== ==

	'''Who's visiting?''' (got it from [[http://openwetware.org/wiki/Kathleen_McGinness Kathleen]], who thanks [[Barry Canton\|Barry]]!)		'''Who's visiting?''' (got it from [[http://openwetware.org/wiki/Kathleen_McGinness Kathleen]], who thanks [[Barry Canton\|Barry]]!)

Jwood1313 at 20:35, 9 August 2006

2006-08-09T20:35:15Z

←Older revision		Revision as of 20:35, 9 August 2006
Line 23:		Line 23:

	Finally, we have also begun a more clinical project, using mass spectroscopy technology to find FA binding proteins. Again in collaboration with the Semmes laboratory, we have adapted the mass spec to analyze sera from patients with pediatric malignancies in order to identify unique protein markers of disease.		Finally, we have also begun a more clinical project, using mass spectroscopy technology to find FA binding proteins. Again in collaboration with the Semmes laboratory, we have adapted the mass spec to analyze sera from patients with pediatric malignancies in order to identify unique protein markers of disease.
		+
		+	==Who is Visiting Us?==
		+
		+	'''Who's visiting?''' (got it from [[http://openwetware.org/wiki/Kathleen_McGinness Kathleen]], who thanks [[Barry Canton\|Barry]]!)
		+
		+	<html>
		+	<a href="http://clustrmaps.com/counter/maps.php?url=http://openwetware.org/wiki/Kupfer_Lab" id="clustrMapsLink"><img src="http://clustrmaps.com/counter/index2.php?url=http://openwetware.org/wiki/Kupfer_Lab" border=1 alt="Locations of visitors to this page"onError="this.onError=null; this.src='http://www.meetomatic.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://clustrmaps.com/'">
		+	</a>
		+	</html>

Jwood1313 at 19:14, 4 August 2006

2006-08-04T19:14:31Z

←Older revision		Revision as of 19:14, 4 August 2006
Line 16:		Line 16:
	[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]		[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]

-	<font face="trebuchet ms" size="+1"> Our lab studies the relationship of genomic instability and the propensity towards development of cancer. Specifically, we focus on the genetic syndrome [http://www.fanconi.org/ Fanconi anemia] (FA). FA serves as a paradigm where the disciplines of development, genetics, and molecular oncology come together. Like other cancer susceptibility syndromes, such as [http://www.atcp.org/ ataxia telangiectasia] and [http://www.xps.org/ xeroderma pigmentosum,]FA patients exhibit a unique hypersensitivity to DNA crosslinking agents, which is the key to the biology of FA. Unlike the other syndromes, exceedingly little is known about FA. To learn more about FA, please visit our [http://openwetware.org/wiki/Kupfer_Lab:Research/ research link.]	+	<font face="trebuchet ms" size="+1"> Our lab studies the relationship of genomic instability and the propensity towards development of cancer. Specifically, we focus on the genetic syndrome [http://www.fanconi.org/ Fanconi anemia] (FA). FA serves as a paradigm where the disciplines of development, genetics, and molecular oncology come together. Like other cancer susceptibility syndromes, such as [http://www.atcp.org/ ataxia telangiectasia] and [http://www.xps.org/ xeroderma pigmentosum,]FA patients exhibit a unique hypersensitivity to DNA crosslinking agents, which is the key to the biology of FA. Unlike the other syndromes, exceedingly little is known about FA. To learn more about FA, please visit our [http://openwetware.org/wiki/Kupfer_Lab:Research research link.]

	We have three other ongoing projects related to FA. First, we have begun to purify the protein complexes containing gene products that are defective in 2 additional hematopoietic failure syndromes, [http://en.wikipedia.org/wiki/Diamond-Blackfan_anemia/ Diamond-Blackfan anemia (DBA)] and congenital dyserythropoietic anemia (CDA).		We have three other ongoing projects related to FA. First, we have begun to purify the protein complexes containing gene products that are defective in 2 additional hematopoietic failure syndromes, [http://en.wikipedia.org/wiki/Diamond-Blackfan_anemia/ Diamond-Blackfan anemia (DBA)] and congenital dyserythropoietic anemia (CDA).

Jwood1313 at 19:12, 4 August 2006

2006-08-04T19:12:38Z

←Older revision		Revision as of 19:12, 4 August 2006
Line 16:		Line 16:
	[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]		[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]

-	<font face="trebuchet ms" size="+1"> Our lab studies the relationship of genomic instability and the propensity towards development of cancer. Specifically, we focus on the genetic syndrome [http://www.fanconi.org/ Fanconi anemia] (FA). FA serves as a paradigm where the disciplines of development, genetics, and molecular oncology come together. Like other cancer susceptibility syndromes, such as [http://www.atcp.org/ ataxia telangiectasia] and [http://www.xps.org/ xeroderma pigmentosum,]FA patients exhibit a unique hypersensitivity to DNA crosslinking agents, which is the key to the biology of FA. Unlike the other syndromes, exceedingly little is known about FA. To learn more about FA, please visit our research link.	+	<font face="trebuchet ms" size="+1"> Our lab studies the relationship of genomic instability and the propensity towards development of cancer. Specifically, we focus on the genetic syndrome [http://www.fanconi.org/ Fanconi anemia] (FA). FA serves as a paradigm where the disciplines of development, genetics, and molecular oncology come together. Like other cancer susceptibility syndromes, such as [http://www.atcp.org/ ataxia telangiectasia] and [http://www.xps.org/ xeroderma pigmentosum,]FA patients exhibit a unique hypersensitivity to DNA crosslinking agents, which is the key to the biology of FA. Unlike the other syndromes, exceedingly little is known about FA. To learn more about FA, please visit our [http://openwetware.org/wiki/Kupfer_Lab:Research/ research link.]

	We have three other ongoing projects related to FA. First, we have begun to purify the protein complexes containing gene products that are defective in 2 additional hematopoietic failure syndromes, [http://en.wikipedia.org/wiki/Diamond-Blackfan_anemia/ Diamond-Blackfan anemia (DBA)] and congenital dyserythropoietic anemia (CDA).		We have three other ongoing projects related to FA. First, we have begun to purify the protein complexes containing gene products that are defective in 2 additional hematopoietic failure syndromes, [http://en.wikipedia.org/wiki/Diamond-Blackfan_anemia/ Diamond-Blackfan anemia (DBA)] and congenital dyserythropoietic anemia (CDA).

Jwood1313 at 19:11, 4 August 2006

2006-08-04T19:11:05Z

←Older revision		Revision as of 19:11, 4 August 2006
Line 12:		Line 12:
	</center>		</center>
	</div><br>		</div><br>
		+
	=='''Welcome to the Kupfer lab at The University of Virginia'''==		=='''Welcome to the Kupfer lab at The University of Virginia'''==
	[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]		[[Image:Figure1.tiff\|thumb\|400px\|right\|'''Fanconi anemia (FA) protein pathway.''' The FA core complex localizes to chromatin during the S phase and in response to DNA damage. Within the core complex, both FANCA and FANCG are phosphorylated (P). In the presence of an intact core complex, FANCD2 is monoubiquitinated (Ub) on K561 and colocalizes in nuclear foci with BRCA1, where it carries out its roles in DNA repair and/or cell cycle control. FANCD2 is a phosphorylation target of kinases ATM and perhaps ATR, a phosphorylation that is necessary to maintain the S-phase checkpoint. At mitosis, FANCG is phosphorylated, and the core complex is excluded from the nucleus and condensed chromatin.]]

Jwood1313 at 19:17, 3 August 2006

2006-08-03T19:17:31Z

←Older revision		Revision as of 19:17, 3 August 2006
Line 4:		Line 4:
	<div style="padding: 20px; color: #ffffff; background-color: #3333CC; width: 620px">		<div style="padding: 20px; color: #ffffff; background-color: #3333CC; width: 620px">
	<center>		<center>
-
	[[Kupfer Lab\| <font face="trebuchet ms" size="+1" style="color:#ff9900"> '''Home''' </font>]]		[[Kupfer Lab\| <font face="trebuchet ms" size="+1" style="color:#ff9900"> '''Home''' </font>]]
	[[Kupfer Lab:Contact \| <font face="trebuchet ms" size="+1" style="color:#ff9900"> '''Contact''' </font>]]		[[Kupfer Lab:Contact \| <font face="trebuchet ms" size="+1" style="color:#ff9900"> '''Contact''' </font>]]
Line 11:		Line 10:
	[[Kupfer Lab:Reprints \| <font face="trebuchet ms" size="+1" style="color:#ff9900"> '''Publications''' </font>]]		[[Kupfer Lab:Reprints \| <font face="trebuchet ms" size="+1" style="color:#ff9900"> '''Publications''' </font>]]
	[[Kupfer Lab:Research \| <font face="trebuchet ms" size="+1" style="color:#ff9900"> '''Research''' </font>]]		[[Kupfer Lab:Research \| <font face="trebuchet ms" size="+1" style="color:#ff9900"> '''Research''' </font>]]
-
	</center>		</center>
	</div><br>		</div><br>